Gara Jalqabaatti › Lymphoma › Massachusetts
Qorannoo klinikaalii Lymphoma Massachusetts keessatti
Qorannoo 33 Lymphoma f Massachusetts keessatti hirmaatuu jiru.
Magaalota Massachusetts keessatti
Takkalaa qorannoo (Ingiliffa)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07015242A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Beth Israel Deaconess Medical Center - Research, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07192471Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
- Mass General Brigham, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07014293A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
- Mass General Hospital, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07013435A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Hanga umuriin 25 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT04094610Epco, Zanu, Ritux for R/R FL or MZL
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06563596AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Boston
- Research Site, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06137144CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
12 Months – 21 Years · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Boston
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 18 · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT07509151Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT04588922A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT04104776Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT07426484The CARDIOPROTECT Trial
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Ado-2026 · NCT07654426DALY II USA/ MB-CART2019.1 for DLBCL
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT04792489A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0026), Boston
Namoota walitti qabaa jiraSadarkaa 1/2
6 Months – 17 Years · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT02332668A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Wax-2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 18-Cam-2026 · NCT01790152Remote Monitoring and Symptom Management Digital Application
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Elb-2026 · NCT07553572Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Elb-2026 · NCT05646576CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Elb-2026 · NCT03328078Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Elb-2026 · NCT06923397A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 66 · Saalaa hunda · Haaromfame 17-Bit-2026 · NCT06859424Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT06510309Odronextamab in Low Tumor Volume Advanced FL
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT07128641Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT06510361A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Bit-2026 · NCT05800366Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Gur-2026 · NCT06475235BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Gur-2026 · NCT06854003CONFIRM: Magnetic Resonance Guided Radiation Therapy
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Gur-2026 · NCT04368702Avo In R/R And Previously Untreated MCL
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ama-2026 · NCT04855695Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Mud-2025 · NCT07052695A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Mud-2025 · NCT06986174HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2025 · NCT06487247Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.